Bromantane: maladaptive learning and stimulant-use hypotheses — WO2025040956A2
Davin RAUTIOLA · 2025 · WO2025040956A2 · patent family 94731432
Published 2025-02-27.
Reported patent results
Reported findings
The patent describes short-term self-reported reductions in stimulant use and cravings, not a controlled addiction-treatment result.
Exploratory, uncontrolled, self-reported human observations over four weeks; total enrollment is not established from the narrative.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Stimulant-use observations | Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeks | Self-report; no biochemical confirmation or control group established · Four-week observation |
| Opioid-use observation | One opioid-dependent participant reported reduced use and cravings | Qualitative individual observation; no numerical reduction given |
| Comorbid symptoms | Reported improvement in irritability, rumination-related insomnia and other symptoms | Self-rated 5-point scales; figure-level individual values not transcribed |
Participant selection, missing group denominators, no control and self-report prevent efficacy claims. Proposed effects on extinction learning were not directly established by these observations.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This 2025 publication proposes bromantane in methods addressing maladaptive learning and stimulant-use disorders.
The indexed WO status is member-specific; this filing is not a completed clinical addiction trial and does not establish the status of every national family member.
- Publication
- WO2025040956A2 ↗ · 2025-02-27
- Earliest priority / filing
- 2023-08-09 / 2024-08-10
- Original applicant / assignee
- Individual
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 94731432 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Drug to treat stimulant addiction
Inventors: Davin RAUTIOLA.
WO2025040956A2 · US20260191802A1 · EP4734971A2 · KR20260049775A · CN121729226A · AU2024326725A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The indexed WO status is member-specific; this filing is not a completed clinical addiction trial and does not establish the status of every national family member.
- Participant selection, missing group denominators, no control and self-report prevent efficacy claims. Proposed effects on extinction learning were not directly established by these observations.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-94731432. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Davin RAUTIOLA. Bromantane: maladaptive learning and stimulant-use hypotheses — WO2025040956A2 WO2025040956A2 · patent family 94731432 2025.
Molekul research summary: https://molekul.io/research/patent-wo2025040956a2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry